Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM

Status: Recruiting
Phase: Phase 1
Diagnosis: Lymphoma
NCT ID: NCT02061761 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID:

 

The purpose of this study is to characterize the safety, tolerability, dose limiting toxicities and maximum tolerated dose of BMS-986016 administered to subjects with relapsed or refractory chronic lymphocytic leukemia, lymphomas and Multiple myeloma

 

Conducting Institutions:
Brigham and Women's Hospital, Dana-Farber Cancer Institute

Overall PI:
Philippe Armand, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Kathleen McDermott, kmcdermott@partners.org

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Part A: - Chronic Lymphocytic Leukemia - Hodgkin Lymphoma - Non Hodgkin Lymphoma - Part B: - Chronic Lymphocytic Leukemia - Hodgkin Lymphoma - Diffuse Large B-cell Lymphoma - Mantle Cell Lymphoma - Progressed, or been refractory to at least one prior standard therapy, including radiation, immunotherapy, cytotoxic chemotherapy, and select antibody (anti-CD20, Alemtuzumab, or Brentuximab) therapy - Not eligible for or declined transplantation or any standard therapy known to be life prolonging or life saving - Subjects without prior exposure to immune cell modulating antibody regimens such as anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1), anti-programmed cell death protein ligand 1 (PD-L1), anti-PD-L2, anti-KIR, anti-CD137, or anti-OX40 antibodies. Prior anti-CD20, Alemtuzumab or Brentuximab antibody therapy is allowed - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - At least 1 lesion with measurable disease - Willing to consent to allow a pre-treatment bone marrow biopsy - Willing to consent to a pre-treatment tumor biopsy or allow the acquisition of an existing tumor sample Exclusion Criteria: - Primary cutaneous lymphoma, lymphoproliferative diseases associated with primary immune deficiencies, and lymphomas associated with human immunodeficiency virus (HIV) infection - Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease (controlled CNS metastases are allowed) - Autoimmune disease
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients


    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us
award

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.

award

Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters